elanco animal health inc. - ELAN

ELAN

Close Chg Chg %
22.18 -0.20 -0.88%

Closed Market

21.99

-0.20 (0.88%)

Volume: 5.89M

Last Updated:

Dec 4, 2025, 3:59 PM EDT

Company Overview: elanco animal health inc. - ELAN

ELAN Key Data

Open

$21.93

Day Range

21.60 - 22.13

52 Week Range

8.02 - 23.66

Market Cap

$11.02B

Shares Outstanding

496.86M

Public Float

492.76M

Beta

1.86

Rev. Per Employee

N/A

P/E Ratio

308.50

EPS

$0.07

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

5.39M

 

ELAN Performance

1 Week
 
-5.50%
 
1 Month
 
2.33%
 
3 Months
 
19.32%
 
1 Year
 
75.92%
 
5 Years
 
-25.15%
 

ELAN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 17
Full Ratings ➔

About elanco animal health inc. - ELAN

Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. Its products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, TruCan, AviPro, Baytril, Catosal, Denagard, and Experior. The company was founded in 1954 and is headquartered in Indianapolis, IN.

ELAN At a Glance

Elanco Animal Health, Inc.
450 Elanco Circle
Indianapolis, Indiana 46221
Phone 1-877-352-6261 Revenue 4.44B
Industry Biotechnology Net Income 338.00M
Sector Health Technology 2024 Sales Growth 0.498%
Fiscal Year-end 12 / 2025 Employees 9,450
View SEC Filings

ELAN Valuation

P/E Current 308.505
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 17.817
Price to Sales Ratio 1.357
Price to Book Ratio 0.982
Price to Cash Flow Ratio 11.13
Enterprise Value to EBITDA 10.951
Enterprise Value to Sales 2.252
Total Debt to Enterprise Value 0.444

ELAN Efficiency

Revenue/Employee 469,735.45
Income Per Employee 35,767.196
Receivables Turnover 4.408
Total Asset Turnover 0.329

ELAN Liquidity

Current Ratio 2.445
Quick Ratio 1.248
Cash Ratio 0.356

ELAN Profitability

Gross Margin 43.005
Operating Margin 5.654
Pretax Margin 10.993
Net Margin 7.614
Return on Assets 2.506
Return on Equity 5.487
Return on Total Capital 3.207
Return on Invested Capital 3.00

ELAN Capital Structure

Total Debt to Total Equity 72.90
Total Debt to Total Capital 42.163
Total Debt to Total Assets 35.231
Long-Term Debt to Equity 71.67
Long-Term Debt to Total Capital 41.452
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Elanco Animal Health Inc. - ELAN

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
4.76B 4.41B 4.42B 4.44B
Sales Growth
+45.57% -7.43% +0.14% +0.50%
Cost of Goods Sold (COGS) incl D&A
2.69B 2.44B 2.48B 2.53B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
716.00M 682.00M 694.00M 662.00M
Depreciation
160.00M 89.00M 92.00M 95.00M
Amortization of Intangibles
556.00M 593.00M 602.00M 567.00M
COGS Growth
+32.74% -9.26% +1.56% +2.06%
Gross Income
2.08B 1.97B 1.94B 1.91B
Gross Income Growth
+66.43% -5.06% -1.62% -1.50%
Gross Profit Margin
+43.55% +44.66% +43.88% +43.01%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.77B 1.59B 1.61B 1.66B
Research & Development
369.00M 321.00M 327.00M 344.00M
Other SG&A
1.40B 1.26B 1.28B 1.31B
SGA Growth
+33.95% -10.55% +1.64% +2.85%
Other Operating Expense
- - - -
-
Unusual Expense
673.00M 188.00M 1.16B 172.00M
EBIT after Unusual Expense
(371.00M) 196.00M (836.00M) 79.00M
Non Operating Income/Expense
68.00M (12.00M) (82.00M) 748.00M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
264.00M 256.00M 277.00M 339.00M
Interest Expense Growth
+69.23% -3.03% +8.20% +22.38%
Gross Interest Expense
264.00M 256.00M 277.00M 339.00M
Interest Capitalized
- - - -
-
Pretax Income
(567.00M) (72.00M) (1.20B) 488.00M
Pretax Income Growth
+15.63% +87.30% -1,559.72% +140.84%
Pretax Margin
-11.90% -1.63% -27.05% +10.99%
Income Tax
(95.00M) 6.00M 36.00M 150.00M
Income Tax - Current - Domestic
1.00M 12.00M (6.00M) (12.00M)
Income Tax - Current - Foreign
58.00M 51.00M 122.00M 274.00M
Income Tax - Deferred - Domestic
(10.00M) (21.00M) (14.00M) 2.00M
Income Tax - Deferred - Foreign
(144.00M) (36.00M) (66.00M) (114.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(472.00M) (78.00M) (1.23B) 338.00M
Minority Interest Expense
- - - -
-
Net Income
(472.00M) (78.00M) (1.23B) 338.00M
Net Income Growth
+15.73% +83.47% -1,478.21% +127.46%
Net Margin Growth
-9.91% -1.77% -27.87% +7.61%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(472.00M) (78.00M) (1.23B) 338.00M
Preferred Dividends
- - - -
-
Net Income Available to Common
(472.00M) (78.00M) (1.23B) 338.00M
EPS (Basic)
-0.9688 -0.1597 -2.5005 0.6842
EPS (Basic) Growth
+23.65% +83.52% -1,465.75% +127.36%
Basic Shares Outstanding
487.20M 488.30M 492.30M 494.00M
EPS (Diluted)
-0.9688 -0.1597 -2.5005 0.6797
EPS (Diluted) Growth
+23.65% +83.52% -1,465.75% +127.18%
Diluted Shares Outstanding
487.20M 488.30M 492.30M 497.30M
EBITDA
1.02B 1.07B 1.02B 913.00M
EBITDA Growth
+131.31% +4.72% -4.32% -10.49%
EBITDA Margin
+21.36% +24.17% +23.09% +20.57%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 24.333
Number of Ratings 17 Current Quarters Estimate 0.115
FY Report Date 12 / 2025 Current Year's Estimate 0.929
Last Quarter’s Earnings 0.19 Median PE on CY Estimate N/A
Year Ago Earnings 0.91 Next Fiscal Year Estimate 1.029
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 10 15 15
Mean Estimate 0.12 0.35 0.93 1.03
High Estimates 0.16 0.38 0.98 1.12
Low Estimate 0.09 0.30 0.90 0.98
Coefficient of Variance 16.47 6.27 1.87 3.81

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 9
OVERWEIGHT 0 0 0
HOLD 3 3 6
UNDERWEIGHT 1 1 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Elanco Animal Health Inc. in the News